Go Pro
NASDAQ:STEX

Biosig Technologies Q4 2025 Earnings Report

Biosig Technologies logo
$0.84 +0.04 (+5.25%)
As of 04:00 PM Eastern

Biosig Technologies EPS Results

Actual EPS
-$8.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biosig Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biosig Technologies Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

Biosig Technologies Earnings Headlines

SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices.tc pixel
See More Biosig Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biosig Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biosig Technologies and other key companies, straight to your email.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion. The technology is intended to integrate with existing electrophysiology lab equipment and workflows, supporting procedures such as ablations used to treat atrial fibrillation and other arrhythmias. By enhancing signal fidelity, the company aims to support procedural efficiency and clinical decision-making for electrophysiologists and hospital electrophysiology labs.

Biosig positions its product development around clinical validation and regulatory pathways common to medical device commercialization, and it targets adoption by hospitals, specialty clinics and physician groups that perform invasive cardiac electrophysiology procedures. The company pursues clinical studies and collaborations to demonstrate the clinical utility of its technology and to support broader commercialization within the medical community.

View Biosig Technologies Profile